SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

"What's Updog?" is a Community Led token.

UpDog

UpDog is trending as the community highlights its multi-year track record and organic growth on the Solana network while actively encouraging others to load their bags. Participants are rallying behind the ticker with memes and dad jokes, emphasizing the project's presence on the Jupiter strict list as a core point of interest.

ETHGas is a Blockspace Infrastructure protocol that decomposes Ethereum blockspace into tradable, composable block units, enabling real‑time block production and laying the foundation for a crypto‑native commodities market for gas. By restructuring gas as a financial primitive, ETHGas unlocks: - Faster block times (sub‑second confirmations vs 12‑second Ethereum blocks) through real‑time sequencing. - A futures/forward market for gas, enabling the creation of a native Ethereum yield curve. - Gas abstraction for end users via the Open Gas Initiative, removing gas volatility and shifting costs to protocols. - Commoditization of blockspace, similar to energy or metals markets in traditional finance.

ETHGas

GWEI is gaining attention as a momentum-driven Ethereum ecosystem token following new listings on major exchanges and growing optimism surrounding upcoming legislative clarity in the crypto sector. Community members are actively discussing its price resilience and staking utility while monitoring broader market catalysts for a potential bull cycle.

Aerodrome Finance is a next-generation AMM designed to serve as Base's central liquidity hub, combining a powerful liquidity incentive engine, vote-lock governance model, and friendly user experience. Aerodrome inherits the latest features from Velodrome V2.

Aerodrome Finance

Aerodrome Finance is attracting significant community attention as investors debate its role as a key liquidity hub on the Base ecosystem, with many closely tracking its ongoing revenue generation and supply-reduction efforts. While some discuss the potential for long-term growth driven by institutional interest and upcoming network expansions, others are navigating recent price volatility and debating the merits of accumulation at current levels.

RAGE GUY (RAGE) is a cryptocurrency inspired by the Rage Guy meme, one of the earliest and most recognizable characters from internet rage comics. The project captures the cultural legacy of early meme history and brings it onto the blockchain in tokenized form. It is designed as a community-driven digital asset that celebrates internet culture, nostalgia, and the role memes play in shaping online communities.

Rage Guy

The RAGE crypto community is aggressively promoting its status as a foundational internet meme, emphasizing its restoration of original rage comic tools and domains to drive viral engagement. Investors are heavily focused on building long-term conviction and community-led growth, positioning the asset as an undervalued cultural staple with aspirations to reach major market milestones.

4DMT operates as a clinical-stage genetic medicines company focused on inventing and developing genetic medicines to treat large market diseases in ophthalmology, pulmonology and cardiology. It develops genetic medicines using its proprietary invention platform, Therapeutic Vector Evolution. It combines the power of the Nobel Prize-winning technology, directed evolution, with approximately one billion synthetic AAV capsid-derived sequences. Its product design, development and manufacturing engine create a valuable and diverse product pipeline. The company is currently advancing five clinical-stage and two preclinical product candidates, each tailored to address rare and large market diseases. 4DMT was founded by David H. Kirn, Melissa Kotterman, Theresa Janke, and David Schaffer on September 12, 2013 and is headquartered in Emeryville, CA.

4D Molecular Therapeutics Inc

4D Molecular Therapeutics is generating significant investor attention as the company advances its 4D-150 gene therapy following positive clinical data in diabetic macular edema. While some community members are debating the company's valuation relative to its cash position and clinical timelines, others are closely monitoring high short interest as a potential catalyst for volatility.

Dash (DASH) is digital cash designed to offer financial freedom to everyone. Payments are instant, easy and secure, with near-zero fees. Built to support real life use cases, Dash is the leading decentralized payment solution. Users can purchase goods at thousands of merchants and trade it at major exchanges and brokers around the globe. Since its creation in 2014, Dash has demonstrated leadership in innovation and pioneered groundbreaking features such as: -Two-tier network with incentivized nodes and decentralized project governance (Masternodes) -Instantly settled payments (InstantSend) -Instantly immutable blockchain (ChainLocks) -Optional privacy (PrivateSend)

Dash

Dash is currently trending as the community speculates on potential utility-focused partnerships and monitors the broader resurgence of interest in privacy-oriented tokens. Investors are actively debating its potential to follow the strong price momentum seen in Zcash while navigating volatility driven by shifting Bitcoin sentiment and anticipation of regulatory updates.

What is Amp?  Amp is described as the new digital collateral token offering instant, verifiable assurances for any kind of value transfer. Using Amp, networks like Flexa can quickly and irreversibly secure transactions for a wide variety of asset-related use cases.  How does Amp work?  Amp claims to offer a straightforward but versatile interface for verifiable collateralization through a system of collateral partitions and collateral managers. Where collateral partitions can be designated to collateralize any account, application, or even transaction, and carry balances which are directly verifiable on the Ethereum blockchain, collateral managers are smart contracts that can lock, release, and redirect collateral in these partitions as needed in order to support value transfer activities. Amp supports a wide variety of use cases for collateralization, and also introduces the concept of predefined partition strategies, which can enable special capabilities such as collateral models through which tokens can be staked without ever leaving their original address.

AMP Token

AMP is attracting intense community attention as traders speculate on the potential passage of the Clarity Act, which proponents believe will solidify the token's status as a digital commodity and unlock its utility for institutional payments. While many users remain optimistic about the project's long-term infrastructure role, the discussion is polarized by deep frustration over prolonged price stagnation, accusations of artificial volume manipulation, and skepticism regarding the timing of enterprise adoption.

Dumb SEND IT

Dumb SEND IT ($DSIT) is gaining traction as investors flock to the newly launched, low-cap meme coin, with the community actively rallying to drive growth through social media engagement and trending efforts. Supporters are focused on the developer's commitment to transparency and periodic airdrops as they work to overcome early liquidity hurdles and build momentum on Solana-based platforms.

Dogecoin is an open-source digital currency based on the "Doge" meme that functions as a peer-to-peer medium for fast payments and digital tipping. Unlike projects backed by corporate entities, its value is driven by a global community, and the project is managed by a decentralized group of volunteers and the non-profit Dogecoin Foundation rather than a formal company.  Originally created in 2013 by software engineers Billy Markus and Jackson Palmer as a market parody, the project held no public sale or venture capital rounds. The network operates as a fork of LuckyCoin, which itself was a fork of Litecoin, using a proof of work consensus mechanism. It employs the Scrypt algorithm to ensure the mining process remains fast and efficient, with new blocks processed every 60 seconds. A unique technical feature is its use of merged mining, allowing miners to secure Dogecoin simultaneously with other Scrypt-based networks like Litecoin.  To keep transaction fees low and the network running indefinitely, Dogecoin features an uncapped supply where new coins are added forever. In a major regulatory milestone in March 2026, a joint SEC and CFTC framework officially classified Dogecoin as a digital commodity, placing it in the same asset category as gold or oil.

Dogecoin

Dogecoin is facing heightened community debate as investors weigh long-term bullish sentiment against ongoing consolidation and frustration over price stagnation. The discourse is fueled by a mix of speculative trading activity and interest in broader crypto market shifts, with many participants actively discussing potential breakout catalysts.

The TROLL token on the Solana network is a meme coin inspired by internet trolling culture, designed for entertainment and community engagement with no intrinsic value. Built on Solana’s blockchain, it leverages the network’s fast transactions and low fees to appeal to meme enthusiasts. Launched on decentralized exchanges, TROLL aims to foster a fun, community-driven ecosystem through social media, influencer partnerships, and viral marketing, embodying the playful spirit of online trolling.

Troll

The $TROLL community is heavily promoting the coin as a classic memetic powerhouse, drawing comparisons to other high-profile internet culture tokens. Investors are actively discussing the project's roots in viral Rage Comics while pushing for broader market adoption through community-driven content and social media awareness.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>Mizuho stated in its note that AET Pharma is the sole remaining generic challenger that has yet to settle with Harmony Biosciences.</li><li>The firm believes Harmony’s Wakix franchise should be viewed as protected and fully intact through 2030.</li><li>Mizuho also noted that Harmony's lawsuit is a "significant development" and a "major positive" for the company.</li></ul>Shares of Harmony Biosciences Holdings Inc. (HRMY) soared more than 18% in Tuesday’s midday trade after analysts at Mizuho announced that they have learned of a new patent lawsuit filed by the company.According to TheFly, Mizuho analysts stated that Harmony Biosciences has sued AET Pharma for allegedly infringing a patent covering an amorphous formulation of pitolisant.<a href="https://stocktwits.com/symbol/HRMY">Harmony Biosciences shares</a> were up over 14% in Tuesday’s midday trade. Retail sentiment on Stocktwits about the company trended in ‘bullish’ territory, with message volume at ‘high’ levels at the time of writing.<h2 class="st-heading-2">What Is The Lawsuit About?</h2>Mizuho stated in its note that AET Pharma is the sole remaining generic challenger that has yet to settle with Harmony Biosciences. The lawsuit covers pitolisant, which was initially developed by Bioprojet and subsequently licensed exclusively by Harmony for the development, manufacture, and commercialization of pitolisant in the U.S.The firm now believes the Harmony Wakix franchise should be considered protected and fully intact through 2030. It also noted that Harmony's lawsuit is a "significant development" and a "major positive" for the company.Mizuho contended that this lawsuit should also remove a major overhang on HRMY stock stemming from concerns that a generic version of pitolisant could be launched before 2030.The firm reiterated its ‘Outperform’ rating on Harmony, with a $50 price target, implying an upside of about 50% from current levels.Koyfin data shows that the average 12-month price target for Harmony is $42, implying an upside of about 27% from current levels. Of the 11 analysts covering the stock, six have either a ‘Strong Buy’ or a ‘Buy’ recommendation, four have a ‘Hold’ rating, and one has a ‘Strong Sell’ recommendation.<h2 class="st-heading-2">What Is Pitolisant Used For?</h2>Pitolisant, originally developed to treat excessive daytime sleepiness and cataplexy in narcolepsy patients, is also being evaluated by Harmony Biosciences for use in individuals with Prader-Willi syndrome.The company also has two pitolisant tablet formulations, namely Pitolisant GR and Pitolisant HD.Harmony is developing Pitolisant GR to enable treatment initiation within the therapeutic dose range. Pitolisant HD is a reformulated version designed to improve how the drug works in the body and to target additional symptoms, such as fatigue, in patients with narcolepsy.Harmony announced in February this year that the U.S. Food and Drug Administration (FDA) approved Wakix (pitolisant) for the treatment of cataplexy in pediatric narcolepsy.“With this approval, clinicians now have the option to prescribe WAKIX to treat excessive daytime sleepiness, cataplexy, or both, in patients 6 years and older with narcolepsy,” said Harmony Biosciences’ Chief Medical and Scientific Officer, Kumar Budur.<a href="https://stocktwits.com/symbol/HRMY">HRMY stock</a> is down 10% year-to-date, but up 18% over the past 12 months. The iShares Core S&amp;P Small-Cap ETF (IJR) is up 43% over the past 12 months, while the iShares Russell 2000 ETF (IWM) is up 51%.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/velo-stock-soars-best-gains-4-months-what-is-fueling-rally/cZBI8d9RI6e">VELO Stock Soars 38%, Races Toward Best Single-Day Move In 4 Months — What Is Fueling The Rally?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Representative image of a stock chart on black background. | Image source: Getty Images

HRMY Stock On Track For Best Intraday Gains In 18 Months — What Did Mizuho Analysts Say?

Mizuho analysts stated that they have learned that Harmony Biosciences has filed a lawsuit against AET Pharma for allegedly infringing a patent covering an amorphous formulation of pitolisant.

Equity

A JetBlue Airways Airbus A321 airplane approaches San Diego International Airport for a landing from Boston on April 20, 2025 in San Diego, California. 

JetBlue CEO Vows Cash Pile Will Prevent Bankruptcy In 2026: Report 

Bloomberg reported on Monday, citing a memo to employees from CEO Joanna Geraghty, that the airline has sufficient liquidity and access to additional capital.

<ul class="summary-bullets"><li>The company said that it is announcing its preliminary net sales in advance as it expects to be interacting with investors and members of the ophthalmology community at an annual meeting in Washington DC later this week .</li><li>In the Middle East and some other parts of the EMEA and APAC regions, net sales were negatively affected by significant geopolitical and macroeconomic challenges.</li><li>STAAR also noted that it shipped minimal quantities of certain products to China during the quarter to manage the excess inventory with distributors and the inventory is now within targeted range.</li></ul>Shares of STAAR Surgical Company (STAA) rallied more than 19% after-hours on Wednesday after the company said that its first quarter (Q1) net sales are expected to exceed $90 million, ahead of Wall Street expectations of $67.59 million.The company reported net sales of $42.6 million for the corresponding quarter last year. &nbsp;STAAR Surgical said that it is announcing its preliminary net sales in advance, before its quarterly earnings, as it expects to be interacting with investors as well as members of the ophthalmology community at an annual meeting in Washington DC later this week.<h2 class="st-heading-2">Geographical Distinctions</h2>STAAR, which makes vision correction solutions that reduces or eliminates the need for glasses or contact lenses, said that it is pleased with its net sales in China, its largest market, for the quarter. China accounted for the majority of the increase in net sales, combined with double digit growth in the Americas, it said.However, in the Middle East and some other parts of the EMEA and APAC regions, net sales were negatively affected by significant geopolitical and macroeconomic challenges, resulting in a decline in sales in parts of those regions, the company said.The Lake Forest, California-headquartered company warned that sales growth could continue to be negatively affected in these regions. It also noted that it shipped minimal quantities of certain products to China during the quarter to manage the excess inventory with distributors and the inventory is now within targeted range.“Our higher net sales, combined with our significantly improved cost structure, are expected to drive a meaningful improvement in adjusted EBITDA (core profit) for the first quarter,” said Deborah Andrews, Interim Co-CEO.STAAR Surgical is expected to report its full first quarter earnings in early May. Wall Street on average expects adjusted core profit for the quarter to come in at $5.40 million.<h2 class="st-heading-2">How Did Retail Traders React?</h2>On Stocktwits, retail sentiment around STAA stock jumped from ‘bearish’ to ‘bullish’ territory over the past 24 hours, while message volume rose from ‘normal’ to ‘extremely high’ levels. &nbsp;A Stocktwits user expressed hopes for some price target revisions after the announcement.<stembedurl>https://www.stocktwits.com/StockBraker/message/649769413</stembedurl>Another termed it a “turnaround moment.”<stembedurl>https://www.stocktwits.com/TheBullishTrade/message/649761840</stembedurl><a href="https://stocktwits.com/symbol/STAA">STAA stock</a> has gained 38% over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/tesla-chinese-rival-beat-it-with-first-us-long-haul-electric-truck-delivery/cZJf7VDRIAA">Tesla’s Chinese Rival Beat It With First US Long Haul Electric Truck Delivery — What Does This Mean For The EV Giant?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Staar Surgical logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

Why Did STAA Stock Surge More Than 19% After-Hours Today?

STAAR Surgical Company announced preliminary net sales for Q1, expected to exceed $90 million. 

<ul class="summary-bullets"><li>Matt Schultz, Chief Executive Officer and Chairman of CleanSpark, said that the company’s core Bitcoin mining operations provide cash flow to fund the company’s strategic investments.</li><li>This includes securing the company’s first hyperscale customer in AI and high-performance computing, while actively building out its talent pipeline.</li><li>The company continues to have 13,561 Bitcoin on its balance sheet.</li></ul>Shares of Bitcoin miner Cleanspark (CLSK) fell at market open on Wednesday after the company announced it had sold 70% of the Bitcoin (BTC) it mined in the month of March.<a href="https://stocktwits.com/symbol/CLSK/">CLSK’s stock</a> dropped more than 3% in morning trade amid&nbsp;<a href="https://stocktwits.com/news-articles/markets/cryptocurrency/hedge-against-bitcoin-beats-btc-amid-crypto-market-dip/cZJJ8hPRIpf">broader weakness</a> in the crypto and equities markets. On Stocktwits, retail sentiment around the shares improved to ‘neutral’ from ‘bearish’ over the past day, while chatter dipped to ‘normal’ from ‘high’ levels.&nbsp;<figure class="image"><img src="https://news.stocktwits-cdn.com/Screenshot_2026_04_07_102644_png_c687b28843.webp" alt="Screenshot 2026-04-07 102644.png" width="1251" height="144"><figcaption>CLSK retail sentiment and message volume on April 7 as of 9:35 a.m. ET | Source: Stocktwits</figcaption></figure><h2 class="st-heading-2">CleanSpark Sells 460 Bitcoin</h2>CleanSpark said it had holdings of 13,363 Bitcoin at the end of February and mined another 658 Bitcoin in March. However, at the end of the month the tally of Bitcoin on its balance sheet was at 13,561 BTC, instead of 14,021.&nbsp;The company sold 460 Bitcoin out of the 658 BTC it had mined over the course of the month at an average price of $71,396 for a total of $32.8 million. Most of the Bitcoin was sold at spot prices, while the rest was adjusted to address call and put exercises as well as other trading activities.&nbsp;Bitcoin’s price fell over 2% in the last 24 hours to around $67,900. Retail sentiment around the apex cryptocurrency on Stocktwits&nbsp;It added that it saw&nbsp;an operational hashrate of 50 Exahashes per second (EH/s) and an average operating hashrate of 47.3 EH/s over the past month. The company reported 1.8 gigawatts (GW) under contract with 808 megawatts (MW) currently utilized to support the fleet’s operational hashrate.<h2 class="st-heading-2">CleanSpark Sells Bitcoin To Fund AI-HPC Pivot</h2>CleanSpark is among the horde of Bitcoin miners, including Riot Platforms (RIOT), MARA Holdings (MARA),&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/bitcoin-supply-tugofwar-riot-mara-sell-strategy-buying/cZJJr55RIpj">selling the apex cryptocurrency</a> for some flexibility on their balance sheets to support their pivot towards artificial intelligence (AI) and high-performance computing (HPC) workloads."We continue to make significant headway toward securing our first hyperscale customer in AI and high-performance computing, while actively building out our talent pipeline to support these high-margin growth initiatives,” said Matt Schultz, Chief Executive Officer and Chairman of CleanSpark, adding that company’s core Bitcoin mining and digital asset management operations provide cash flow to fund the company’s strategic investments.In comparison, peers like Core Scientific (CORZ), Cipher Mining (CIFR) and MARA Holdings (MARA) have already&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/mara-stock-is-rallying-today-what-is-all-the-buzz-about/cZTGrGCRIRW">announced</a> multi-year deals to host AI workloads.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/cryptocurrency/hedge-against-bitcoin-beats-btc-amid-crypto-market-dip/cZJJ8hPRIpf">‘Hedge Against Bitcoin’ Outperforms BTC Amid Crypto Market Dip On Record Shielded Supply</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, a person holds a smartphone displaying the logo of CleanSpark Inc.

CleanSpark Sold 70% Of The Bitcoin It Mined In March For Over $71,000 Apiece

Most of the Bitcoin was sold at spot prices, while the rest was adjusted to address call and put exercises as well as other trading activities. 

Cryptocurrency

Most of the Bitcoin was sold at spot prices, while the rest was adjusted to address call and put exercises as well as other trading activities. 


<ul class="summary-bullets"><li>Fuel prices for Chicago, Houston, Los Angeles and New York averaged $4.57 a gallon last Friday, up nearly 83% since the day before the war began, CNBC&nbsp;reported, citing data from Argus.&nbsp;</li><li>Airfares have increased globally since the U.S. and Israel’s attack on Iran on Feb. 28.</li></ul>JetBlue Airways (JBLU) is reportedly raising bag fees for its flyers as rising fuel prices due to the ongoing Iran war begin to&nbsp;weigh on the company.“As we experience rising operating costs, we regularly evaluate how to manage those costs while keeping base fares competitive and continuing to invest in the experience our customers value,” JetBlue said in a statement to CNBC.Fuel prices for Chicago, Houston, Los Angeles and New York averaged $4.57 a gallon last Friday, up nearly 83% since the day before the war began, CNBC reported, citing data from Argus.&nbsp;Airfares have increased globally since the U.S. and Israel’s attack on Iran on Feb. 28. The recent rise in checked bag fees is the latest indication that airlines are passing higher fuel costs onto American travelers. After labor, jet fuel is the largest expense for airlines.<h2 class="st-heading-2">Rising Fuel Prices&nbsp;</h2>Crude oil jumped on Monday and stayed well above $100 a barrel mark, signalling a prolonged Iran war.&nbsp;Benchmark U.S. oil futures gained $3.24 a barrel Monday to settle at $102.88, their first close above $100 since 2022 when Russia invaded Ukraine and rattled energy markets, as per Wall Street Journal.&nbsp; Brent crude futures for May delivery were as high as $116 Monday.&nbsp;The United States Oil Fund ETF (USO) closed 4.5% higher on Monday, while the ProShares Ultra Bloomberg Crude Oil ETF (UCO) ended the day 1.7% higher.&nbsp;<h2 class="st-heading-2">Retail reaction</h2>Retail sentiment around JBLU&nbsp;stock trended in ‘bullish’ territory amid ‘extremely high’ message volume.&nbsp;Shares in the company have fallen around 10% so far this year.&nbsp;

JetBlue Airbus A321neo passenger aircraft spotted departing from the runway of Amsterdam Schiphol Airport in the Netherlands on April 10, 2025.

JetBlue Airways Reportedly Raises Baggage Fees As Rising Fuel Costs Bite

 As JetBlue experiences rising operating costs, it regularly evaluates how to manage those costs while keeping base fares competitive, the airline told CNBC in a statement. 

<ul class="summary-bullets"><li>Cantor noted that, even though Adma Biologics released a statement following the short report, the firm expected more specific feedback addressing the direct claims made in the report.</li><li>Cantor analyst Kristen Kluska also cited a lack of clarity and concerns around increased days sales outstanding and accounts receivable for downgrading Adma Biologics.</li><li>ADMA stock has declined nearly 29% since Culper’s short report was released on Tuesday.</li></ul>Adma Biologics Inc. (ADMA) has been downgraded by analysts at Cantor Fitzgerald, with the firm citing disappointment among investors following the company’s response to a short report.According to TheFly, Cantor stated that its discussions with several investors pointed to a lack of direct communication from Adma Biologics after Culper Research released its&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/adma-stock-drops-after-culper-research-alleges-channel-stuffing/cZ3nq7uRI1i">short report</a> on Tuesday.Cantor downgraded Adma Biologics to ‘Neutral’ from ‘Overweight’ without a price target. ADMA stock has declined nearly 29% since Culper’s short report was released.<a href="https://stocktwits.com/symbol/ADMA">Adma Biologics’ shares</a> were down more than 2% in Thursday’s pre-market trade. Retail sentiment on Stocktwits around the company trended in the ‘extremely bullish’ territory, with message volumes at ‘extremely high’ levels at the time of writing.<h2 class="st-heading-2">What Is Cantor Concerned About?</h2>Cantor noted that, even though Adma Biologics released a statement following the short report, the firm expected more specific feedback addressing the direct claims made in the report.Cantor analyst Kristen Kluska also cited a lack of clarity and concerns around increased days sales outstanding and accounts receivable for downgrading Adma Biologics.According to Koyfin, the average 12-month price target for ADMA stock is $23.5, implying a return potential of 144% from current levels. Of the three analyst ratings, two have a ‘Buy’ recommendation, while one has a ‘Hold’ rating.<h2 class="st-heading-2">What Did The Short Report Flag?</h2>Culper Research stated in its short report that Adma Biologics’ sales growth is driven by a “de facto channel stuffing scheme.” The firm stated that Adma’s revenue declined 3% in 2025, after adjusting for sales inflation, while the company reported a 20% growth.The short seller also noted that the sales of Adma’s flagship product, Asceniv, have been inflated by 40% to 76%. “We believe the ASCENIV growth story is total fiction owing entirely to channel stuffing,” Culper added.The firm added that, based on its interactions with two high-level employees at one of Adma’s largest distributors, the biopharmaceutical company induced the distributor to stock excess Asceniv by offering rebates and extended payment terms to meet the distributor's order expectations.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>One user on the platform stated that even if a part of Culper’s short report is true, it gives the company a black eye.<stembedurl>https://stocktwits.com/Tradeswithyourmom/message/648578343</stembedurl>However, a bullish user dismissed the short report, saying that there is nothing to see here.<stembedurl>https://stocktwits.com/glacier64/message/648588280</stembedurl><a href="https://stocktwits.com/symbol/ADMA">ADMA stock</a> is down 47% year-to-date and 52% over the past 12 months. The iShares Core S&amp;P Small-Cap ETF (IJR) is up 17% over the past 12 months, while the S&amp;P Biotech ETF (XBI) is up 42%.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/iran-us-ceasefire-plan-maximalist-unreasonable-white-house-weekend-talks/cZ3YvQ5RISH">Iran Reportedly Says US Ceasefire Proposal Is 'Extremely Maximalist And Unreasonable' Even As White House Plans Weekend Talks</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the ADMA Biologics logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

ADMA Stock Downgraded By Cantor As ‘Channel Stuffing’ Claims Shake Investor Confidence

Cantor stated that its discussions with several investors pointed to a lack of direct communication from Adma Biologics after Culper Research released its short report on Tuesday.

<ul class="summary-bullets"><li>Oppenheimer analyst Kostas Biliouris, meanwhile, said Sarepta's data in the programs "appear promising."</li><li>The firm now awaits additional data in the second half of 2026 to better assess Sarepta's programs.</li></ul>Shares of Sarepta Therapeutics (SRPT) closed 35% higher on Wednesday despite Wall Street raising concerns on the company’s early clinical results for two of its programs in neuromuscular diseases.Leerink analyst Joseph Schwartz said the initial data released by the company earlier on Wednesday in genetic diseases myotonic dystrophy type 1 (DM1) and facioscapulohumeral muscular dystrophy type 1 (FSHD1) are "a bit of a mixed bag." While it seems like they can achieve "impressive" muscle concentration, the DM1 data are "very limited and safety remains an open debate," said the analyst, who has a ‘Market Perform’ rating on Sarepta shares.Oppenheimer analyst Kostas Biliouris, meanwhile, said Sarepta's data in the programs "appear promising." However, the early nature of data and use of different sample sizes across measurements may bias the results, preventing conclusion, the analyst told investors in a research note. The firm awaits additional data in the second half of 2026 to better assess Sarepta's programs. The firm has an ‘Outperform’ rating on Sarepta with a $37 price target.<h2 class="st-heading-2">Sarepta’s Trial Data</h2>Sarepta said earlier in the day that early results from the studies of its investigational siRNA treatment SRP-1001 in FSHD1 and DM1 demonstrated dose- dependent muscle exposure, early biomarker effects, and favorable tolerability, which the company expects will lead to better clinical efficacy.Both DM1 and FSDH1 are genetic disorders caused by overexpression of mutant proteins or toxic mRNA and characterized by progressive muscle weakness. The experimental treatment is designed to reduce, or knock down, the production of DUX4 protein in skeletal muscle.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around SRPT stock jumped from ‘bullish’ to ‘extremely bullish’ territory over the past 24 hours, while message volume rose from ‘low’ to ‘extremely high’ levels.<a href="https://stocktwits.com/symbol/SRPT">SRPT stock</a> has dropped 68% over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/terns-buyout-deal-ignites-optimism-for-enliven-therapeutics-blood-cancer-portfolio/cZ3Y6W6RIjP">Terns Buyout Deal Ignites Optimism For Enliven Therapeutics’s Blood Cancer Portfolio</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Sarepta Therapeutics logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

SRPT Stock Clocks Highest Daily Gain In Nearly 8 Years After Rare Muscle Disorders Study Data But Wall Street's Not Wholly Convinced

Leerink analyst Joseph Schwartz said the initial data released by the company in genetic diseases DM1 and FSHD1 are "a bit of a mixed bag."

<ul class="summary-bullets"><li>DigitalOcean said that it intends to use the net proceeds from the offering to make investments in additional infrastructure capacity.</li><li>It also plans to further strengthen its balance sheet by paying down its existing Term Loan A, and use proceeds for general corporate purposes.</li><li>DigitalOcean is the Agentic Inference Cloud built for AI-native and Digital-native enterprises scaling production workloads.</li></ul>DigitalOcean (DOCN) shares plunged nearly 9% during extended hours of trading on Tuesday after it announced that it has commenced an underwritten public offering of $700 million of its shares.&nbsp;Additionally, DigitalOcean intends to grant the underwriters a 30-day option to purchase up to an additional $105 million of shares.The company in a statement said that the offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.<h2 class="st-heading-2">Purpose To Use Proceeds</h2>DigitalOcean said that it intends to use the net proceeds from the offering to make investments in additional infrastructure capacity, beyond what it has previously communicated, to support customer demand for DigitalOcean’s cloud&nbsp;or AI platform.&nbsp;It also plans to further strengthen its balance sheet by paying down its existing Term Loan A, and use proceeds for general corporate purposes. DigitalOcean is in advanced discussions to secure this additional data center capacity to support its growth, it said.&nbsp;<h2 class="st-heading-2">What Is DigitalOcean</h2>DigitalOcean is the agentic inference cloud built for AI-native and digital-native enterprises scaling production workloads. The platform combines production-ready GPU infrastructure with a full-stack cloud to deliver operational simplicity and predictable economics at scale. The company has more than 640,000 customers.<h2 class="st-heading-2">Retail Reaction</h2>Retail sentiment around DOCN trended in ‘bullish’ territory amid ‘high’ message volume.&nbsp;Shares in the company have jumped 75% year-to-date.&nbsp;&nbsp;

Shares of DigitalOcean have jumped 75% year-to-date. 

Why Is DigitalOcean Plunging Today?

DigitalOcean intends to grant the underwriters a 30-day option to purchase up to an additional $105 million of shares.

<ul class="summary-bullets"><li>With additional data from its confirmatory late-stage trial, Sarepta is now seeking to shift the approval type to traditional for the two DMD therapies.&nbsp;</li><li>Oppenheimer analyst Andreas Argyrides sees the sNDA filing as positive as it removes the risk of Amondys/Vyondys being pulled from the market for the next year.</li><li>Earlier this week, Sarepta also said that screening and enrollment are underway in a cohort of its study aimed at developing an enhanced safety protocol for its DMD gene therapy Elevidys.</li></ul>Sarepta Therapeutics (SRPT) said on Thursday that it intends to make certain submissions to the U.S. Food and Drug Administration regarding two of its Duchenne muscular dystrophy therapies by the end of April, in a move applauded by Wall Street.Sarepta is now looking to submit supplemental new drug applications (sNDA) seeking conversion of the accelerated approvals of Amondys 45 and Vyondys 53 to traditional approvals, with the help of data from a confirmatory late-stage study.The company said that the FDA has confirmed that data from the trial can be submitted as part of the application. However, the adequacy of the data to support conversion to traditional approval will be a matter of review, the company said.<h2 class="st-heading-2">Analyst Takeaway</h2>Oppenheimer analyst Andreas Argyrides sees the sNDA filing as positive as it removes the risk of Amondys/Vyondys being pulled from the market for the next year. The analyst added that it also signals positive FDA feedback during a meeting, pointing to potential sNDA approval.The firm reiterated an ‘Outperform’ rating on Sarepta with a price target of $37 on the shares.<h2 class="st-heading-2">About Vyondys And Amondys</h2>Vyondys 53 and Amondys 45 are both FDA-approved, weekly intravenous antisense oligonucleotide therapies from Sarepta for Duchenne muscular dystrophy (DMD), a severe, progressive genetic disorder primarily affecting young boys, characterized by muscle degeneration. Both therapies now have an accelerated approval.While Accelerated Approval (AA) allows faster market access for drugs treating serious conditions, based on surrogate endpoints that likely predict clinical benefit, Traditional Approval requires direct evidence of clinical benefit. Accelerated approval requires post-marketing confirmatory trials to prove clinical efficacy to prevent the approval from being withdrawn.With additional data from its confirmatory late-stage trial, Sarepta is now seeking to shift the approval type to traditional for the two DMD therapies.<h2 class="st-heading-2">Sarepta’s Update For Elevidys</h2>Earlier this week, Sarepta also <a href="https://stocktwits.com/news-articles/markets/equity/sarepta-shares-rise-as-company-begins-enrollment-in-gene-therapy-safety-enhancement-study/cZ3PezERIQd">said</a> that screening and enrollment are underway in a cohort of its study aimed at developing an enhanced safety protocol for its gene therapy, Elevidys, in non-ambulant individuals with Duchenne muscular dystrophy.FDA-approved Elevidys came under scrutiny last year over concerns of acute liver failure and associated patient deaths. While the company resumed shipments to ambulatory patients after a temporary pause in July 2025, it is now working to address the safety concerns in patients who cannot walk.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around SRPT stock stayed within the ‘bearish’ territory over the past 24 hours, while message volume remained at ‘low’ levels.<a href="https://stocktwits.com/symbol/SRPT">SRPT stock</a> is down 79% over the past 12 months.&nbsp;For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration a Sarepta Therapeutics logo is seen on a smartphone and a pc screen. (Photo Illustration by Pavlo Gonchar/SOPA Images/LightRocket via Getty Images)

Sarepta’s Plans To Seek Traditional Approval For DMD Therapies ‘Positive,’ Says Wall Street Analyst

Sarepta is now looking to submit supplemental new drug applications (sNDA) seeking conversion of the accelerated approvals of Amondys 45 and Vyondys 53 to traditional approvals. 

Vanguard or iShares: Which Offers the Better Small-Cap ETF?

Key PointsVanguard Small-Cap ETF charges half the expense ratio of iShares Core S&P Small-Cap ETF, but both are extremely low-cost...

IJR
iShares Core S&P Small-Cap ETF

Feed

News

Sentiment

Fundamentals

Info

Latest IJR News

IJRiShares Core S&P Small-Cap ETF